Drug intelligence / Profile preview

Guangsi Yulin

Development stage: Preclinical
Lead developer: Capital Development Project Fund
Administration: Oral

Overview

Guangsi Yulin is a Traditional Chinese Medicine (TCM) decoction currently undergoing clinical investigation for its potential therapeutic effects in patients with asthenospermia. As a decoction, it is typically a multi-ingredient herbal preparation. The ongoing research focuses on evaluating its impact on the sperm DNA fragmentation index in affected individuals.

Other names: Guang Si Yu Lin Tang广嗣育麟汤

Beyond the preview

Go deeper on Guangsi Yulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangsi Yulin.

Explore the full profile